CRDL
Cardiol Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$1.10
+0.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.08
From 52W high−51.86%
Volume630903.00
Market cap$133.66M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.08
From 52W high
−51.86%
Volume
630903.00
Market cap
$133.66M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.4x
P/E (TTM)
—
RSI (14)
20.3
MomentumView details →
1D Return
+0.00%
YTD Return
+14.80%
SummaryUpdated Jun 1, 2026
Cardiol Therapeutics Inc. (NASDAQ:CRDL) is a clinical-stage Canadian biopharmaceutical company founded in 2017 and headquartered in Oakville, Ontario. The company went public in January 2019 and focuses on developing innovative therapies to treat cardiovascular diseases through anti-fibrotic and anti-inflammatory approaches. As a clinical-stage company, Cardiol has no commercial products yet and is currently conducting Phase II/III trials for its lead drug candidate, CardiolRx, targeting heart-related conditions including COVID-19 cardiovascular complications and acute myocarditis.
Similar companies
Latest newsMore news →
Cardiol Therapeutics achieved its Phase III MAVERIC enrollment target of 110 patients ahead of schedule and expanded the pivotal trial of CardiolRx™ to up to 150 patients.27d agoCardiol Therapeutics announced the exercise of warrants for over USD 7 million in proceeds, strengthening its balance sheet ahead of Phase III MAVERIC trial data in recurrent pericarditis.34d ago